$6 million Brain Canada grant awarded to McGill to develop virtual integrated patient platform
NMD4C are pleased to share that The Neuro has received a $6 million grant from Brain Canada to fund a new Open Science patient registry to share data with researchers around the world and let patients see how their data is used to develop new treatments for neurological disorders.
The Neuro’s Virtual Integrated Patient Platform (NeuroVIPs) will contain multi-modal data from thousands of patient partners stored across the institution’s various clinical and research platforms, including The Neuro’s Open Biobank. NeuroVIPs will create a digital link between these platforms, so that a patient’s phenotype, genetics, neuroimaging, and other data can be accessed by research teams in one centralized location.
Integrated neuromuscular biobank
We are excited to continue to work with The Neuro and C-BIG as the hub for our virtual neuromuscular biobank, and to apply their neuroinformatic architecture to the cataloging of Canadian neuromuscular tissue samples.
Learn more about the NeuroVIPs project
Read the full press releases from McGill University and Brain Canada to learn more!
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.